Description Omarigliptin (MK-3102) is an oral hypoglycemic agent of super long-lasting dipeptidyl peptidase-4 (DPP-4) developed by Merck & Co., USA. It is administered orally once a week, being able to produce sustained DPP-4 inhibition with a new mechanism of lowering blood sugar. Meanwhile, it does not increase body weight and not cause hypoglycemia and edema. Its mechanism of action is through inhibiting the degrading of the in vivo dipeptidyl peptidase-4 (DPP-4) on the GLP-1, prolonging the action time of glucagon-like peptide-1 (GLP-1), thereby increasing the blood concentration of the endogenous GLP-1 and GIP, and ultimately improving blood glucose control.
GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient (API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and customer service. With the efforts of all the company's employees, it has established long-term and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic and foreign customers. With good comments, our company have made great progress.
Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide customers with efficient services, high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of win-win.
Our company focuses on the future and the world, and will continue to devote itself to technological progress and the development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad to create a better future.